| Literature DB >> 35323885 |
Fredrikke Christie Knudtzen1,2,3, Thøger Gorm Jensen1,4, Nanna Skaarup Andersen1,5, Isik Somuncu Johansen2,3, Joppe W Hovius6, Sigurdur Skarphédinsson1,2,3.
Abstract
BACKGROUND: Our objectives were to improve the following outcomes in patients with Lyme borreliosis (LB) through an educational intervention in general practice: (i) increase the number of hospital referrals on suspicion of LB, (ii) increase the number of cerebrospinal fluid (CSF) tests examined for Borrelia burgdorferi antibody index, (iii) decrease the number of serum-B. burgdorferi antibody tests ordered, (iv) shorten delay from symptom onset to hospital in Lyme neuroborreliosis (LNB) patients, (v) increase LB knowledge among general practitioners.Entities:
Mesh:
Year: 2022 PMID: 35323885 PMCID: PMC9159330 DOI: 10.1093/eurpub/ckac013
Source DB: PubMed Journal: Eur J Public Health ISSN: 1101-1262 Impact factor: 4.424
Figure 1Map of the island of Funen, Langeland and Ærø. Divided by postal codes into areas with a Lyme neuroborreliosis incidence of ≥4.7/100.000 population per year, where general practices were eligible for inclusion (dark blue), and areas with Lyme neuroborreliosis incidence <4.7/100.000 population, not eligible for inclusion (light blue). The areas of gry color are serviced by general practitioners with addresses in other postal codes.
Figure 2Flow chart of inclusion of general practices into an educational intervention about ticks and tick-borne infections on the islands of Funen, Langeland and Ærø.
Presenting the impact of an educational intervention among an intervention group of 49 general practices, compared with a control group (71 general practices) on Funen, Langeland and Ærø, Denmark, in the 2 years before (2017 + 2018) and during/after (2019 + 2020) the intervention
| Before educational intervention | After educational intervention | All | ||||
|---|---|---|---|---|---|---|
| 2017 | 2018 | 2019 | 2020 | |||
| Referrals | Increase after educational intervention | |||||
| Intervention group | 16 | 22 | 28 | 21 |
| 28.9% |
| Control group | 11 | 31 | 43 | 24 |
| 59.5% |
| All | 27 | 53 | 71 | 45 |
| 45.0% |
| Intrathecal antibody tests | Increase after educational intervention | |||||
| Intervention group | 128 (9; 7.0%) | 190 (10; 5.3%) | 203 | 181 (6; 3.3%) |
| 20.8% |
| Control group | 224 (9; 4.0%) | 288 (6; 2.1%) | 306 (7; 2.3%) | 298 (6; 2.0%) |
| 18.0% |
| All | 352 (18; 5.1%) | 478 (16; 3.3%) | 509 (17; 3.3%) | 479 (12; 2.5%) |
| 19.0% |
| Serum antibody tests | Decrease after educational intervention | |||||
| Intervention group | 293 | 255 | 179 | 133 |
| 43.1% |
| Control group | 337 | 338 | 252 | 190 |
| 34.5% |
| All | 630 | 593 | 431 | 323 |
| 38.3% |
Referrals: Number of patients referred from the general practitioners in the two groups under the diagnosis Lyme borreliosis to the Clinical Center for Emerging and Vector-borne Infections at Odense University Hospital. Intrathecal antibody tests: Number of cerebrospinal fluid samples tested for intrathecal production of Borrelia burgdorferi antibodies in patients from the two groups. Serum antibody tests: Number of ordered serum anti-B. burgdorferi antibody tests from the general practitioners in the two groups.
Three tested before intervention.
Number of tests (number positive; % positive).
Thirty-seven tested before intervention (4 positive).
Twenty-one samples ordered before the educational intervention.
Characteristics of 63 patients with Lyme neuroborreliosis in the period 2017–20 from Funen, Langeland and Ærø, Denmark, divided into an intervention group and a control group
| Control group | Intervention group before | Intervention group after | All | ||
|---|---|---|---|---|---|
| Sex, male (%) | 17 (53.1) | 10 (55.6) | 7 (53.9) | 34 (54.0) |
|
| Age, median (IQR) | 53 (36–68) | 68 (48–71) | 58 (45–70) | 58 (40–70) |
|
| Comorbidities | |||||
| 0 | 25 (78.1) | 13 (72.2) | 8 (61.5) | 46 (73.0) |
|
| 1 | 6 (18.8) | 5 (27.8) | 2 (15.4) | 13 (20.6) | |
| ≥2 | 1 (3.1) | 0 | 3 (23.1 ) | 4 (6.4) | |
| Pre-hospital delay, days, median (IQR) | 21 (9–47) | 23 (9–64) | 29 (17–121) | 23 (9–56) |
|
| Residual symptoms after 6 months (%) | 13 (40.6) | 6 (33.3) | 3 (23.1) | 22 (34.9) |
|
| Cognitive symptoms after 6 months (%) | 8 (25.0) | 5 (27.8) | 4 (30.8) | 17 (27.0) |
|
Comorbidities measured by use of the Charlson comorbidity index.